Protopic, Elidel Safety Labeling May Be Reviewed, FDA Tells Pediatric Cmte.

FDA plans to discuss the pediatric safety profile of topical immunosuppressants with Novartis and Fujisawa after an advisory committee recommended stronger warnings about the potential carcinogenicity of Elidel and Protopic